NSCLC and BLBC patients classified as ΔNp63α-, Slug- or FAT2-high had a worse odds of survival compared to the ΔNp63α-, Slug- and FAT2-low patients. The gene discussed is FAT2; the disease is non-small cell lung carcinoma.